Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flow from operating activities:
Net loss	$ (13,762,039)	$ (6,462,645)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	649,441	649,126
Vesting expense	75,901	598,325
Common stock issued for consulting and other	212,792	0
Amortization of debt discount	0	244,830
Gain on valuation of equity-linked instruments and derivative liability	(97,162)	(64,762)
Equity instruments issued management, consultant, and other		52,471
Loss on impairment of goodwill	7,231,093	0
Loss on fixed asset disposal	1,700	0
Changes in assets and liabilities:
Accounts receivable	17,799	60,358
Inventories	(86,931)	(28,291)
Prepaid expense and other assets	(157,827)	39,852
Accounts payable	(38,104)	(430,110)
Accrued expenses and other liabilities	(441,328)	(198,890)
Deferred revenue	(29,457)	101,317
Other long-term liabilities	(3,684)	(88,559)
Net cash used in operating activities:	(6,427,806)	(5,526,978)
Cash flow from investing activities:
Purchase of fixed assets	(233,572)	(610,906)
Acquisition of intangibles	(34,844)	(22,870)
Net cash used in investing activities	(268,416)	(633,776)
Cash flow from financing activities:
Proceeds from issuance of common stock and warrants, net	6,507,050	50,515,810
Proceeds from exercise of warrants into common stock	0	4,495,270
Repayment of debt	0	(4,162,744)
Payment penalties	0	(1,073,470)
Proceeds from issuance of common stock pursuant to equity line	236,009	588,590
Net cash provided by financing activities	6,743,059	50,363,456
Net increase in cash and cash equivalents	46,837	44,202,702
Cash and cash equivalents at beginning of period	28,202,615	678,332
Cash and cash equivalents at end of period	28,249,452	44,881,034
Non-cash transactions:
Shares issued to CEO per agreement related to accrued interest	0	143,573
Shares issued pursuant to convertible debt	0	514,011
Cash paid during period for:
Interest paid	$ 1,439	$ 694,435